The role of current strategies in the future treatment of rheumatoid arthritis

Rheumatology

Volumn 38, Issue SUPPL. 2, 1999, Pages 19-23

  Weinblatt, M E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Combination therapy; Cyclosporin; Cytokine; Methotrexate; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CYCLOSPORIN; METHOTREXATE;

CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYMPTOM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; METHOTREXATE;

EID: 0032692512     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.suppl_1.19     Document Type: Conference Paper

References (25)

1. van Gestel AM, Haagsma CJ, Furst DE, Van Riel PLCM. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs (SAARDs). Baillière's Clin Rheumatol 1997;11:65-82.
2. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996; 39:616-22.
3. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
4. Williams HJ, Willkens RF, Samuelson COJ et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985;28:721-30.
5. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998;25:238-42.
6. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: follow-up after a mean of 13.3 years. Arthritis Rheum 1997;40:984-5.
7. Weinblatt ME, Kaplan H, Germain BF et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum 1990;33:330-8.
8. Weinblatt ME, Polisson R, Blotner SD et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36: 613-9.
9. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26:794-804.
10. Kremer JM, Alarcon GS, Weinblatt ME et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
11. Kremer JM, Alarcón GS, Lightfoot RWJ et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
12. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
13. Berg KJ, Forre O, Bjerkhoel F et al. Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int 1986;29:1180-7.
14. Berg KJ, Forre O, Djoseland O, Mikkelsen M, Narverud J, Rugstad HE. Renal side effects of high and low cyclosporin A doses in patients with rheumatoid arthritis. Clin Nephrol 1989;31:232-8.
15. Boers M, Dijkmans BA, van Rijthoven AW, Goei TH, Cats A. Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. J Rheumatol 1990;17:38-42.
16. Tugwell P, Bombardier C, Gent M et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990;335:1051-5.
17. Pasero G, Priolo F, Marubini E et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006-15.
18. Forre O. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994;37: 1506-12.
19. Rodriguez F, Krayenbuhl JC, Harrison WB et al. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Arthritis Rheum 1996;39:1491-8.
20. Schiff M. Emerging treatments for rheumatoid arthritis. Am J Med l997;102:11S-5S.
21. Stucki G, Langenegger T. Management of rheumatoid arthritis. Curr Opin Rheumatol 1997;9:229-35.
22. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
23. Kremer JM. Disease-modifying drugs for RA: current patterns of clinical use. J Musculoskel Med 1996;13:11-9.
24. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
25. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350: 309-18.